ATE485258T1 - Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase - Google Patents

Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase

Info

Publication number
ATE485258T1
ATE485258T1 AT02704938T AT02704938T ATE485258T1 AT E485258 T1 ATE485258 T1 AT E485258T1 AT 02704938 T AT02704938 T AT 02704938T AT 02704938 T AT02704938 T AT 02704938T AT E485258 T1 ATE485258 T1 AT E485258T1
Authority
AT
Austria
Prior art keywords
acid derivatives
medication
beta
inhibiting
producing
Prior art date
Application number
AT02704938T
Other languages
English (en)
Inventor
Barry Potter
Atul Purohit
Michael Reed
Nigel Vicker
Original Assignee
Sterix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterix Ltd filed Critical Sterix Ltd
Application granted granted Critical
Publication of ATE485258T1 publication Critical patent/ATE485258T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
AT02704938T 2001-03-08 2002-03-07 Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase ATE485258T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105772.8A GB0105772D0 (en) 2001-03-08 2001-03-08 Use
PCT/GB2002/001060 WO2002072084A2 (en) 2001-03-08 2002-03-07 Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity

Publications (1)

Publication Number Publication Date
ATE485258T1 true ATE485258T1 (de) 2010-11-15

Family

ID=9910270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02704938T ATE485258T1 (de) 2001-03-08 2002-03-07 Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase

Country Status (7)

Country Link
US (1) US20040147494A1 (de)
EP (1) EP1381357B1 (de)
AT (1) ATE485258T1 (de)
AU (1) AU2002238737A1 (de)
DE (1) DE60238042D1 (de)
GB (1) GB0105772D0 (de)
WO (1) WO2002072084A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
JP4601936B2 (ja) 2002-10-29 2010-12-22 株式会社ミノファーゲン製薬 Mcp−1産生抑制のための薬学的組成物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE10307388A1 (de) * 2003-02-21 2004-09-02 Cognis Deutschland Gmbh & Co. Kg Glyzyrrhetinsäureester
CA2515129A1 (en) * 2003-02-21 2004-09-10 Merck & Co., Inc. Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues
WO2004080535A2 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777
JP2006522744A (ja) * 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
DE10340747A1 (de) * 2003-08-29 2005-04-07 Ludwig Prof. Dr. Wildt Stimulierung des Brustwachstums durch Erhöhung der intrazellulären Cortisolkonzentration
WO2005027882A1 (en) 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
GB0325745D0 (en) * 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
DE102004040690A1 (de) * 2004-08-20 2006-03-02 Universitätsklinikum Schleswig-Holstein Selektiver Inhibitor der 11beta-Hydroxysteroid Dehydrogenase
GB0418877D0 (en) * 2004-08-24 2004-09-29 Univ Edinburgh Heart
US20080153791A1 (en) * 2005-03-18 2008-06-26 Onpharm Gmbh 11Beta -Hydroxysteroid Dehydrogenases
EP1866298A2 (de) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroiddehydrogenase-hemmer
CN100488979C (zh) * 2005-10-14 2009-05-20 天津药物研究院 甘草次酸-30-酰胺类衍生物及其用途
GB0523550D0 (en) * 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
CA2657674A1 (en) * 2006-02-17 2007-08-23 Wuhan University The application of glycyrrhizic acid and its breakdown product glycyrrhetinic acid for the manufacture of a medicament for the treatment of inflammatory bowel disease
WO2008071169A2 (de) * 2006-12-11 2008-06-19 Universitätsklinikum Schleswig-Holstein Verfahren zur herstellung spezifischer inhibitoren der 11beta-hydroxysteroid-dehydrogenase, insbesondere des typs 1, mit nor-oleanan- oder nor-ursan-grundgerüsten
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
EP2243494A1 (de) * 2009-04-22 2010-10-27 OntoChem GmbH Arzneimittelzusammensetzung, enthaltend einen Steroid-dehydrogenase-reduktase-Hemmer und einen Mineralocorticoidantagonisten.
CN101899081B (zh) * 2009-05-31 2012-09-05 江苏正大天晴药业股份有限公司 甘草次酸酯类衍生物合成方法以及脱氧甘草次酸酯化合物
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TW201221524A (en) * 2010-11-23 2012-06-01 Univ Fu Jen Catholic A compound used to improve diseases caused by aquaporin deficiency
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
US9828326B2 (en) * 2011-12-27 2017-11-28 Northeast Ohio Medical University Amooranin compounds and analogs thereof and related methods of use
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014134413A2 (en) * 2013-03-01 2014-09-04 Revlon Consumer Products Corporation Cyrrhetinic alkyl esters and protected derivatives thereof
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015057862A1 (en) * 2013-10-15 2015-04-23 President And Fellows Of Harvard College Methods and compositions for eradicating leukemic cells
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (de) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetische spirochromanverbindungen
CN111018938B (zh) * 2019-12-10 2021-05-25 中国人民解放军第二军医大学 一种五环三萜类甘草次酸衍生物及制备方法与应用
CN115677813A (zh) * 2021-03-25 2023-02-03 河北中医学院 化合物在tmem16a激动剂中的应用
CN113912665B (zh) * 2021-12-01 2023-03-28 河北维达康生物科技有限公司 一种合成3-甲氧基-18β-甘草次酸的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859328A (en) * 1971-11-03 1975-01-07 Pfizer 18 beta-glycyrrhetinic acid amides
US3766206A (en) * 1971-11-03 1973-10-16 Pfizer 18beta-glycyrrheting acid amides useful as antiulcer agents
US3934027A (en) * 1973-05-03 1976-01-20 Pfizer Inc. 18β-Glycyrrhetinic acid amides useful as antiulcer agents
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
IT1075675B (it) * 1977-03-16 1985-04-22 Isf Spa Derivati dell'acido oleanoico
JPS588044A (ja) * 1981-07-06 1983-01-18 Maruzen Seiyaku Kk 11−デオキソグリチルレチン酸水素マレ−ト及びそれを有効成分とする医薬
JPS63135351A (ja) * 1986-11-28 1988-06-07 Sanwa Kagaku Kenkyusho Co Ltd グリチルレチン酸誘導体、その製法及び該化合物を有効成分とする抗潰瘍剤
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent

Also Published As

Publication number Publication date
US20040147494A1 (en) 2004-07-29
WO2002072084A8 (en) 2003-01-09
EP1381357B1 (de) 2010-10-20
WO2002072084A3 (en) 2002-11-21
WO2002072084A2 (en) 2002-09-19
GB0105772D0 (en) 2001-04-25
DE60238042D1 (de) 2010-12-02
AU2002238737A1 (en) 2002-09-24
EP1381357A2 (de) 2004-01-21

Similar Documents

Publication Publication Date Title
ATE485258T1 (de) Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase
SE0001899D0 (sv) New compounds
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200615266A (en) Organic compounds
SE0202462D0 (sv) Novel use
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
EP1807412A1 (de) Als tyrosinkinaseinhibitoren geeignete zyklische harnstoffe
SG148177A1 (en) Novel cis-imidazolines
ATE437872T1 (de) Proteinkinaseinhibitoren
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE60202958D1 (de) Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
MY133527A (en) Isoquinoline derivatives
DE602004015406D1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
SE9903894D0 (sv) Novel compounds
TW200616636A (en) Novel compounds
MXPA04007643A (es) Inhibidores de la adhesion celular mediada por integrina alb2.
DE602004025935D1 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung
DE502005003310D1 (de) Cycloalkyl substituierte 7-amino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1949893A3 (de) Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen
PL365258A1 (en) Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties